4.8 Letter

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Koen B. Pouwels et al.

Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.

NATURE MEDICINE (2021)

Article Medicine, General & Internal

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Hiam Chemaitelly et al.

Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Multidisciplinary Sciences

Human IgG and IgA responses to COVID-19 mRNA vaccines

Adam Wisnewski et al.

Summary: Study on 4 subjects showed that COVID-19 mRNA vaccines effectively induce spike antigen-specific IgG and IgA, but there are marked differences in their persistence in serum.

PLOS ONE (2021)

Article Public, Environmental & Occupational Health

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Catherine M. Brown et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)